Actively Recruiting
Evaluating Asciminib Safety and Effectiveness in Children with Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase
Led by Novartis Pharmaceuticals · Updated on 2026-10-15
50
Participants Needed
34
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying asciminib, a drug being evaluated for children aged 1 to under 18 years with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase Ph CML-CP. The study includes newly diagnosed patients as well as those resistant or intolerant to previous treatments, with or without a specific T315I mutation. The goal is to assess how well asciminib works and how safe it is in this pediatric population. Participants will receive asciminib either as a pediatric formulation based on weight or an adult tablet, taken with or without food depending on the form. The study includes three groups of children based on their diagnosis and mutation status. Treatment duration is not fixed and continues as long as appropriate. The study will last up to 5 years after the last participant starts treatment to allow thorough evaluation of safety, growth, development, and effectiveness. During the study, children will have regular assessments including blood tests for leukemia response at multiple times up to 96 weeks, and monitoring of growth, bone age, and sexual development for up to 240 weeks. Researchers will also evaluate the drugs behavior in the body through pharmacokinetic measurements. Safety and disease progression will be closely followed throughout the study period.
CONDITIONS
Brief Title
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here